The Anatomy of Autism

Introduction: A Convergent Cascade Model for Immune-Derived Autism

Autism spectrum disorder does not have a single cause. A mechanistically distinct subgroup — immune-derived autism — has a single convergent mechanistic node through which a wide range of initiating insults produce the same downstream outcome.

A substantial and growing body of independent research has established immune dysfunction as a consistent finding across familial autoimmunity, maternal immune activation, neuroinflammation, and autoantibody generation in ASD subgroups — with autoantibodies in a subset of children documented to target specifically GABAergic interneurons in the cerebellum and superficial cortical layers,^[51] the cell class whose silencing is central to the cascade proposed here.

The initiating insults described in this document are diverse. No two children with immune-derived autism necessarily share the same combination of founding conditions. Prenatal hormonal exposures, birth circumstances, environmental toxicants, genetic variants affecting acid production, nutritional depletions, and pathogenic infections may each contribute independently or in combination. Yet a significant proportion of affected children share the same outcome because all of these conditions, regardless of their origin, converge on the same series of intermediate mechanisms and arrive at the same convergent point: the silencing of somatostatin-14 interneurons in the cortex, hippocampus, and hypothalamus.

This convergence explains what has challenged autism researchers for decades. The phenotype appears heterogeneous from the outside because affected children entered the cascade at different points and through different combinations of initiating insults. The phenotype is consistent from the inside because all pathways converge on the same mechanistic node. The apparent heterogeneity of ASD reflects variation in the upstream cascade steps that drove SST-14 silencing — not variation in the downstream mechanism that produced the phenotype.

The Three Interneuron States: A Clinical Framework

SST-14 interneuron silencing does not occur as a single discrete event. It progresses through three states that reflect the depth of the suppressive burden and determine which interventions are appropriate for a given patient.

State 1 — transcriptional suppression: The interneuron's structural and metabolic machinery is intact but SST-14 gene expression has been suppressed by NF-κB-mediated cAMP response element-binding protein (CREB) inhibition and autoantibody-mediated surface receptor jamming. This is the most reversible state. Removal of the upstream immune burden — through immunoglobulin therapy — allows CREB to resume driving SST-14 expression, and functional recovery can be relatively rapid.

State 2 — metabolic exhaustion: Chronic quinolinic acid-driven calcium overload and NAD⁺ depletion have damaged mitochondrial function in the interneuron. Even when transcriptional suppression is relieved by immune clearance, the interneuron cannot resume tonic firing because the mitochondrial substrate required to sustain it is depleted. State 2 requires both immune clearance and metabolic restoration before functional recovery is achievable.

State 3 — structural loss: Progressive excitotoxic damage has produced partial interneuron loss. Trophic restoration through growth factors including IGF-1 and brain-derived neurotrophic factor (BDNF), combined with the A2 astrocyte polarization shift that mesenchymal stem cell (MSC) therapy promotes, represents the primary intervention pathway. The A1/A2 astrocyte reversibility established by Liddelow et al.^[9] indicates that even State 3 is not irreversible, but recovery is slower and more dependent on the trophic environment.

Founding Conditions: Initiating Insults and Ongoing Drivers of Gut pH Dysregulation

The cascade initiates when the gut environment shifts toward a higher-than-normal pH, disabling the enzymatic systems required for complete protein digestion. A wide range of independent conditions can produce this pH dysregulation, and in most affected individuals several operate simultaneously. The result is self-perpetuating: the pH elevation that initiates the cascade also generates conditions that maintain it, making resolution unlikely when only a single contributing factor is addressed.

Prenatal and Perinatal Initiating Conditions

Prenatal hormonal or immune disruption

The enteric nervous system and hypothalamic-pituitary axis differentiate between weeks 5 and 12 of gestation. Exogenous hormones, maternal stress hormones, maternal infection, and maternal autoimmune conditions can all alter the development of the acid-producing parietal cell population before birth — producing a gut that enters postnatal life with reduced capacity for adequate hydrochloric acid (HCl) production.

Birth mode and microbial seeding

Cesarean delivery bypasses the birth canal, eliminating the primary maternal microbial seeding event. Hospital-acquired streptococcal species — which directly block the CD26 receptor via streptokinase — can establish dysbiotic colonization from the first days of life, failing to seed the acid-producing commensal populations required for normal gut pH regulation.

Failure to establish nursing

Breast milk contains oligosaccharides that selectively feed acid-producing commensal bacteria. Colostrum shapes early gut immune tolerance. The sucking reflex activates motilin via muscle contraction, establishing the migrating motor complex that drives gut motility from birth. Low muscle tone, premature birth, or formula dependence deprive the gut of these pH-regulating inputs simultaneously.

Oral contraceptive use and maternal nutritional depletion

Combined oral contraceptive pills deplete B6, B12, folate, zinc, and magnesium. Zinc is specifically consequential: it is the essential cofactor for carbonic anhydrase, which generates the hydrogen ions parietal cells use to produce HCl. A woman conceiving shortly after stopping oral contraceptives may begin pregnancy with depleted reserves across all five nutrients.

Folate receptor antibodies

Autoantibodies against folate receptor alpha block methylfolate transport into the brain and cerebrospinal fluid, producing cerebral folate deficiency independent of dietary folate status. This founding vulnerability compounds the methylation failure that adenosine accumulation produces later in the cascade, creating a dual methylation vulnerability from birth.

Genetic variants affecting acid production

Polymorphisms in proton pump genes, carbonic anhydrase variants, and zinc transporter variants reduce parietal cell acid output from birth. methylenetetrahydrofolate reductase (MTHFR) polymorphisms — particularly the C677T variant, documented at elevated frequency in ASD populations^[20,21] — reduce conversion of dietary folate to the active methylfolate form, compounding the adenosine-driven methylation bottleneck of the cascade.

Environmental and Toxic Initiating Conditions

Glyphosate exposure and microbiome depletion

Glyphosate disrupts the shikimate pathway in bacteria, selectively depleting commensal species including Lactobacillus, Bifidobacterium, and Enterococcus faecalis while sparing many gram-negative LPS-producing pathogenic species. Maternal dietary exposure depletes the microbiome seed delivered at birth, favoring the LPS-producing ecology that elevates pH and initiates downstream pepsin failure.^[29]

Mercury and heavy metal exposure

Mercury directly binds to the CD26 receptor site on lymphocyte immune cells, blocking adenosine deaminase (ADA) from binding and initiating the adenosine accumulation that rate-limits the methionine synthase cycle. Pre-1990s dental amalgam fillings, thimerosal, environmental mercury, and dietary fish exposure represent concurrent routes; effects are additive.

Organophosphate and organochlorine pesticide exposure

Organophosphate pesticides inhibit acetylcholinesterase, producing muscarinic receptor downregulation that paradoxically reduces parietal cell acid responsiveness over time. Organophosphate flame retardants (OPFRs) — used in infant sleep surfaces under flammability regulations from 1975 to approximately 2015 — are detected in cord blood, confirming prenatal exposure through maternal body burden.

Viral disruption of adenylyl cyclase signaling

Bordetella pertussis toxin locks inhibitory G-protein Gαi in inactive form, disrupting cAMP generation through the same pathway whose disruption by adenosine accumulation reduces SST-14 gene expression. Herpesviruses including cytomegalovirus and Epstein-Barr virus interact with G-protein regulatory components through similar mechanisms.

Ongoing Drivers That Perpetuate pH Dysregulation

H. pylori infection alkalinises the stomach via urease-generated ammonia, directly elevating gastric pH and damaging parietal cells through inflammatory mechanisms. Recurrent streptococcal infections reintroduce streptokinase, which blocks the CD26 receptor by the same mechanism as opioid peptides and mercury — compounding cumulative CD26 blockade burden with each episode. Chronic sympathetic dominance suppresses vagal tone, reducing parietal cell acetylcholine stimulation and chronically lowering acid output. Proton pump inhibitor therapy, prescribed for reflux that often reflects low motility and fermentation pressure rather than acid overproduction, may relieve the surface symptom while deepening the underlying pH dysregulation.

Once CD26 is blocked by any mechanism, adenosine accumulates, the methionine synthase cycle slows, and the cellular energy available to drive parietal cell activity falls — perpetuating the pH elevation that initiated the opioid peptide accumulation independent of whether the original blocking agent remains present. This is the CD26 self-reinforcing loop.

Constitutional Susceptibility: Why Only Certain Individuals Cross the Cascade Tipping Points

One of the most important challenges to any multi-insult cascade model is the observation that most individuals exposed to the same founding conditions do not develop the condition being modeled. C-section delivery, formula feeding, antibiotic exposure, and glyphosate exposure describe a large fraction of the general pediatric population. Immune-derived autism affects a small minority. The constitutional susceptibility architecture is the answer to that question.

The model is not single-gene determinism. It is a constitutional profile — a combination of genetic, enzymatic, and immunological factors distributed across the cascade that together determine how much biological headroom remains at each step before that step fails. A child with reduced headroom at multiple cascade steps simultaneously has a constitutional burden that makes crossing each tipping point far more likely when the common environmental pressures arrive. The same founding conditions, processed through a different constitutional profile, do not produce the cascade.

Tipping Point 1: Gastric Acid Production Capacity

Constitutional factor: reduced baseline parietal cell acid output. ATP4A and ATP4B proton pump gene variants narrow the margin within which environmental pressures must operate to produce clinically significant pH elevation.^[42] A child with constitutively reduced pump efficiency reaches the pepsin-inactivation threshold under environmental loads that leave most children below it. This tipping point currently carries Level 4 evidence for direct ASD-specific application — proton pump variant studies in ASD cohorts have not yet been published. The mechanistic logic is strong; the epidemiological anchor requires prospective study.

Tipping Point 2: CD26/DPP-IV Adenosine Clearance Capacity

Constitutional factor: constitutively reduced DPP-IV enzymatic efficiency. Bashir and Al-Ayadhi documented significantly lower plasma DPP-IV activity in ASD children versus controls.^[38] EL-Alameey et al. replicated this and added the correlation with casein antibody titers — establishing that reduced DPP-IV activity and casomorphin-driven immune response co-occur in the same children.^[39] Hunter et al. and Shattock et al. independently confirmed the pattern.^[40,41] A child running at constitutively reduced DPP-IV efficiency has no reserve when casomorphin, streptokinase, and mercury simultaneously block remaining capacity. Level 1–2 evidence.

Tipping Point 3: Methylation Cycle Reserve

Constitutional factor: reduced methionine synthase cycle throughput. MTHFR C677T — documented at elevated frequency in ASD populations^[20,21] — reduces methylfolate availability, compounding the adenosine-driven methylation bottleneck. A child with MTHFR C677T homozygous crosses the methylation failure threshold under adenosine loads that heterozygous children tolerate. Level 1 evidence for the variant; Level 2–3 for the causal pathway to IDA.

Tipping Point 4: Inflammatory Resolution Capacity

Constitutional factor: impaired capacity to actively terminate innate immune activation. Specialized pro-resolving mediators (SPMs) — resolvins, protectins, lipoxins — produced via ALOX5, ALOX12, and ALOX15 from omega-3 PUFA substrates are the active off-switch for innate immune activation.^[47,48] A child with ALOX variants reducing SPM production capacity cannot actively terminate LPS-driven immune activation, which persists as the chronic cytokine state driving IDO1 and NF-κB. This is the most novel and least-evidenced tipping point — currently Level 4 for ASD-specific application. Direct ALOX variant studies in ASD populations have not yet been published.

Tipping Point 5: Kynurenine Pathway Excitotoxic Branch Bias

Constitutional factor: KMO variants determining the constitutional QUIN/KYNA ratio. KMO polymorphisms rs2275163 and rs1053230 are associated with altered kynurenic acid levels in schizophrenia cohorts — establishing that KMO genetic variation produces measurable differences in the QUIN/KYNA ratio in living humans.^[45,46] A child with KMO variants favoring QUIN production crosses the excitotoxic threshold at lower IDO1 activation levels. Level 2 evidence from neuropsychiatric populations — direct ASD KMO variant data pending.

Tipping Point 6: Mitochondrial Excitotoxic Buffering Reserve

Constitutional factor: mitochondrial reserve capacity and antioxidant genetics. Frye, Rose, and colleagues documented that ASD lymphoblastoid cell lines exhibit abnormal mitochondrial reserve capacity and increased vulnerability to oxidative stress challenge at baseline.^[43,44] Genetic variations in glutathione pathways — GPX1, GSTM1, SOD2 — correlate with behavioral outcomes. A child with reduced mitochondrial reserve crosses the State 1/State 2 boundary under quinolinic acid loads that children with adequate reserve tolerate in State 1. Level 2 evidence directly in ASD populations.

Tipping Point 7: HLA-Mediated Autoantibody Susceptibility

Constitutional factor: HLA class II architecture. HLA-DR and HLA-DQ alleles determine which self-mimicking peptides from casomorphin, streptokinase, and mercury-modified self proteins trigger autoantibody production through molecular mimicry. The same mechanism that produces anti-CD26 and anti-folate receptor autoantibodies in IDA children operates only in individuals whose HLA architecture presents those peptides as immunogenic. Level 2–3 evidence from autoimmune literature; ASD-specific HLA association data are emerging.

The Constitutional Profile as Predictive Biomarker

The seven tipping points can be operationalized as an additive constitutional burden score — the number of cascade steps at which an individual carries constitutional variants placing them at reduced headroom. A child with a high constitutional burden score is predictably more vulnerable to IDA cascade propagation under the same environmental exposures as a child with a low score. This score extends the diagnostic biomarker panel into a prospective susceptibility screen and is Testable Prediction 7 of the model.

How Elevated Gut pH Disables Pepsin, Blocks Essential Amino Acid Release, and Produces Hidden Malnutrition

Pepsin pH dependence and proline bond cleavage failure

Pepsin is the primary gastric protease responsible for cleaving the proline bonds in casein and gluten proteins. These proline bonds are unusually strong double-helical structures not readily cleaved by small intestinal proteases. Pepsin requires a pH of approximately 2.0 for optimal activity and becomes essentially inactive above pH 4.0. When founding conditions have elevated gastric pH above this threshold, pepsin cannot fulfill its primary digestive function regardless of dietary protein load.

The intact proline-bonded peptide fragments that accumulate are not nutritionally inert. Their rigid corkscrew geometry enables them to resist degradation by small intestinal proteases and to penetrate the intestinal mucosal wall — contributing to the intestinal permeability documented consistently in ASD populations.^[23]

Essential amino acid deficiency and the hidden malnutrition state

Three essential amino acids depend critically on pepsin-mediated proline bond cleavage: phenylalanine, tyrosine, and tryptophan. When pepsin cannot cleave the proline bonds containing them, no amount of dietary protein corrects the resulting deficiency — the building blocks remain locked in undigested peptide fragments excreted rather than absorbed.

The downstream consequence is hidden malnutrition — a child consuming an apparently adequate diet who is biochemically deficient in the three amino acid precursors of dopamine, norepinephrine, serotonin, and melatonin. This deficiency is not detectable by standard dietary assessment and requires amino acid panel testing.

The hidden malnutrition state establishes the first of two independent mechanisms through which tryptophan is depleted in immune-derived autism. The second — indoleamine 2,3-dioxygenase 1 (IDO1)-mediated tryptophan diversion — operates through a completely different mechanism but converges on the same endpoint. Tryptophan-dependent serotonin synthesis is simultaneously limited from above by failed digestion and from below by immune-driven enzymatic diversion.

Opioid Peptide Accumulation and the CCK-Mediated Gut SST-28 Overactivation Cascade

Casomorphin — derived from incompletely digested casein — and gliadorphin — derived from incompletely digested gluten — belong to a class of compounds termed exorphins: peptides originating outside the body that bind to opioid receptors. This binding initiates the first of two distinct cascade pathways.

Opioid receptor binding and the food-seeking reinforcement loop

Casomorphin and gliadorphin bind to mu-opioid receptors throughout the gut and brain, producing opioid-like effects and driving the body to upregulate cholecystokinin (CCK) as a homeostatic response. Two simultaneously operating mechanisms produce characteristic food selectivity: opioid receptor activation produces biochemical reward from dairy and wheat specifically; simultaneously, the body's homeostatic amino acid deficiency detection systems generate food-seeking signals directed toward protein-rich sources — which casein and gluten foods correctly represent. Both drives arrive at the same behavioral output simultaneously, explaining the food selectivity of affected children as a convergent biological phenomenon rather than a behavioral or sensory preference.

CCK overactivation and gut SST-28 dysregulation

Because the opioid peptide load is continuous rather than episodic, the normal CCK off-switch does not fire. Chronic CCK overactivation drives gut SST-28 — the 28-amino-acid form of somatostatin produced by intestinal D-cells — into sustained overexpression. SST-28 is the primary inhibitory regulator of the digestive hormone cascade: it suppresses gastrin, secretin, VIP, motilin, and gastric acid secretion. In immune-derived autism it becomes tonically and globally overactive, suppressing the entire digestive hormone cascade continuously.

CD26 Blockade, Adenosine Accumulation, and Methylation Cycle Impairment

In parallel with the CCK-mediated SST-28 overactivation, the same casomorphin and gliadorphin peptides initiate a second mechanistically distinct cascade pathway through the CD26 receptor — sharing the same upstream trigger but producing entirely different downstream consequences that converge independently on SST-14 interneuron silencing.

CD26 blockade and the adenosine clearance failure

CD26 — also known as dipeptidyl peptidase IV (DPP-IV) — is a multifunctional membrane protein on the surface of lymphocyte immune cells that serves as the binding site for adenosine deaminase (ADA), the enzyme responsible for converting and clearing adenosine from the cell. Casomorphin and gliadorphin bind to the ADA receptor site on CD26, physically preventing ADA from docking and executing adenosine clearance. Streptokinase, mercury, and genetic CD26 receptor variants block the same site by the same mechanism — their effects are additive.^[23]

Adenosine as rate limiter of the methionine synthase cycle

Adenosine directly inhibits methionine synthase, the enzyme at the center of the methylation cycle that converts homocysteine back to methionine and regenerates S-adenosylmethionine (SAMe) — the universal methyl donor. When methionine synthase activity is rate-limited by adenosine, SAMe production falls and S-adenosylhomocysteine (SAH) accumulates. Elevated SAH competitively inhibits the methyltransferase enzymes that perform methylation reactions throughout the cell — simultaneously failing neurotransmitter regulation, immune cell switching, DNA methylation, and cellular energy production through phosphatidylcholine-dependent mitochondrial membrane integrity.

Homocysteine accumulation as a biomarker of methylation failure

Elevated plasma homocysteine with concurrent low plasma cysteine and reduced glutathione represents the laboratory fingerprint of the CD26-adenosine-methylation cascade mechanism. Homocysteine elevation in the presence of normal B12 and folate concentrations suggests functional B12 deficiency — adenosine rate-limiting the cycle despite adequate B12 — or folate receptor antibody-mediated delivery failure.

Physical markers of methylation insufficiency include joint hypermobility, elongated and hyperextensible fingers, pectus excavatum, pale or mottled skin, low muscle tone, fatigue disproportionate to activity, and reduced exercise tolerance. These reflect impaired collagen synthesis downstream of reduced glycine availability through the transsulfuration pathway — the same pathway that reduces cysteine availability for glutathione synthesis.

Intestinal Barrier Disruption, LPS Translocation, and Systemic Immune Activation

The compromised gut barrier does not merely allow peptide fragments into systemic circulation. It creates a conduit through which gram-negative bacterial cell wall components — specifically lipopolysaccharide (LPS) — enter systemic circulation continuously. This LPS translocation is the primary initiating event for the chronic systemic immune activation that drives the upstream IDO1 and nuclear factor kappa B (NF-κB) mechanisms of subsequent cascade steps.

LPS is one of the most potent known activators of the innate immune system. Even at nanogram concentrations it triggers toll-like receptor 4 (TLR4) pattern recognition receptor activation in macrophages and microglia, initiating the production of IL-1β, IL-6, TNF-α, and IFN-γ. Activated microglia produce IL-1α, TNF-α, and complement component C1q — the three signals that drive the astrocyte A1 polarization shift described in the convergence section.

IDO1 Activation, the Kynurenine Pathway, and Excitotoxic Pressure on SST-14 Interneurons

The sustained elevation of IL-1β, IL-6, TNF-α, and IFN-γ generated by LPS translocation activates indoleamine 2,3-dioxygenase 1 (IDO1) — the first rate-limiting step in the kynurenine pathway, diverting tryptophan away from serotonin synthesis toward kynurenine and its downstream metabolites.

IDO1-mediated tryptophan diversion and the double depletion mechanism

The consequence is a double depletion operating from two independent directions simultaneously. From above — pepsin inactivation prevents tryptophan release from dietary proline-bonded protein. From below — IDO1 continuously diverts available tryptophan into the kynurenine pathway. Serotonin synthesis is simultaneously limited by impaired supply and active enzymatic diversion. The kynurenine-to-tryptophan ratio (K:T ratio) in plasma provides a direct quantitative measure of IDO1 activity; a K:T ratio above 0.030 is consistent with active IDO1-driven tryptophan diversion.

Quinolinic acid production and excitotoxic calcium overload

The kynurenine pathway bifurcates: the neuroprotective branch produces kynurenic acid through kynurenine aminotransferase; the neurotoxic branch, driven by kynurenine monooxygenase activated by the same pro-inflammatory cytokines driving IDO1, produces 3-hydroxykynurenine and ultimately quinolinic acid.

Quinolinic acid is a potent endogenous N-methyl-D-aspartate (NMDA) receptor agonist. Its overstimulation of NMDA receptors forces calcium entry into neurons at rates exceeding their mitochondrial buffering capacity. SST-14 interneurons are disproportionately vulnerable: they maintain tonic high-frequency firing demanding continuous ATP production, making them particularly sensitive to mitochondrial energy depletion from quinolinic acid-driven calcium overload.

The disrupted NMDA magnesium block and AMPA disinhibition

Under normal conditions, a magnesium ion occupying the NMDA receptor channel pore prevents calcium entry in the absence of simultaneous membrane depolarization. In immune-derived autism this protection is compromised simultaneously from two directions: magnesium depletion from malabsorption and methylation-dependent magnesium transport failure reduces the blocking ion concentration; AMPA receptor disinhibition from reduced SST-14 inhibitory tone provides persistent membrane depolarization that relieves the magnesium block independent of glutamate binding. Quinolinic acid then overstimulates NMDA receptors that are simultaneously unprotected and persistently depolarized, producing calcium overload substantially greater than either mechanism alone would generate.

NAD⁺ depletion and mitochondrial energy failure

Further downstream, quinolinic acid is converted to NAD⁺. Under chronic IDO1 activation, NAD⁺ consumption by mitochondrial stress response mechanisms exceeds the kynurenine pathway's replacement capacity. The result is cellular NAD⁺ depletion that further compromises the mitochondrial ATP production on which SST-14 tonic firing depends — a self-reinforcing energy failure in the cells most vulnerable to the excitotoxic pressure driving it.

Direct Cytokine-Mediated Suppression of SST-14 Gene Expression via NF-κB and CREB

In parallel with the IDO1-kynurenine excitotoxic arm, the same inflammatory cytokines independently act on SST-14 interneurons through a transcriptional mechanism that directly suppresses SST-14 gene expression. These two arms share the same upstream cytokine trigger but operate through entirely different intracellular mechanisms.

The NF-κB-CREB-SST-14 transcriptional suppression mechanism

Pro-inflammatory cytokines activate NF-κB — nuclear factor kappa B — a master regulator of the cellular inflammatory response. NF-κB activation suppresses CREB — cAMP response element-binding protein — the transcription factor that drives SST-14 gene expression through the somatostatin gene's cyclic AMP response element (CRE, sequence 5'-TGACGTCA-3'), as documented by Montminy and colleagues.^[1] The interneuron's structural and metabolic machinery remains largely intact. Its gene expression has been turned down by the immune environment surrounding it.

To understand why this suppression is so difficult for the cell to overcome, it is necessary to understand the two independent mechanisms by which it operates simultaneously.

How CREB Activation Is Blocked: Two Independent Mechanisms

Mechanism A — NF-κB actively hijacks the transcriptional machinery. The somatostatin CRE requires not only CREB but a co-activator protein called CBP (CREB-binding protein) to initiate transcription. CBP is present in limited quantities within each cell and cannot be rapidly upregulated on demand. When pro-inflammatory cytokines activate NF-κB, NF-κB enters the nucleus and competes directly with CREB for CBP. Under chronic inflammatory conditions, NF-κB dominates this competition — redirecting CBP to serve the inflammatory transcriptional program rather than SST-14 gene expression. CREB is left at the CRE binding site without the co-activator it needs. Simultaneously, NF-κB recruits histone deacetylase (HDAC) enzymes to the chromatin surrounding the somatostatin gene promoter. HDACs remove acetyl groups from histone proteins, tightening the DNA winding and making the CRE physically less accessible to transcription machinery — an epigenetic layer of suppression on top of the CBP competition.^[1]

Mechanism B — Adenosine starvation of the cAMP signal. CREB requires phosphorylation by protein kinase A (PKA) at its serine-133 residue to become active. PKA is activated by cyclic AMP (cAMP). cAMP is produced by adenylyl cyclase from ATP. Adenosine accumulation from CD26 blockade activates inhibitory Gαi-coupled adenosine receptors on SST-14 interneurons, suppressing adenylyl cyclase through Gαi. Reduced adenylyl cyclase activity reduces intracellular cAMP. Reduced cAMP reduces PKA-mediated CREB phosphorylation — independently of NF-κB. The somatostatin gene's CRE is deprived of its activating signal from an entirely different direction simultaneously.^[30]

Mechanism B2 — Mu-opioid receptor: a second independent Gαi input. A second Gαi-coupled receptor suppresses adenylyl cyclase simultaneously and through a distinct receptor: casomorphin and gliadorphin also activate mu-opioid receptors (MOR) directly on SST-14 interneurons, engaging Gαi through a route entirely independent of adenosine accumulation. This mu-opioid Gαi input is present as long as gut-derived opioid peptide load persists, regardless of CD26/adenosine clearance status, and adds approximately 25–60% inhibition of adenylyl cyclase activity to the adenosine input. The two Gαi inputs are additive: restoring adenosine clearance alone is mechanistically insufficient to recover full adenylyl cyclase output while opioid peptide load persists. Both inputs are bypassed simultaneously when adenylyl cyclase is activated directly at its catalytic subunit — the mechanism of forskolin.

Why both mechanisms operating simultaneously is worse than either alone. Mechanism A suppresses CREB even when cAMP is present — by taking away CBP and burying the gene under epigenetic packaging. Mechanism B prevents cAMP from activating CREB in the first place. If only Mechanism A were operating, the cell might partially compensate by generating extra cAMP — flooding enough phosphorylated CREB into the nucleus that some might outcompete NF-κB for CBP. If only Mechanism B were operating, the cell could manage if the inflammatory environment were mild enough that NF-κB was not fully dominating CBP. Both operating simultaneously removes every compensatory route. The CRE lock is present. The CREB key exists. The CBP locksmith is in the cell. The electricity — cAMP — is somewhere in the grid. But the key has no power and the locksmith has been hired away. The SST-14 recipe goes unread.

Where the estrogen compensatory axis fits. The Gq-mER estrogen pathway characterized by Qiu et al.^[35] generates cAMP through a Gαq-mediated route entirely independent of the Gαi-mediated suppression that adenosine uses to cut the conventional cAMP supply. It bypasses Mechanism B but not Mechanism A. In females, this partial back-door electricity partially compensates for cAMP starvation — providing enough phosphorylated CREB that some manages to find CBP and maintain some SST-14 output. In prepubertal males, this back door is closed — opening only at puberty when aromatase converts testosterone to estradiol in the brain.

This transcriptional suppression is the most clinically reversible form of SST-14 silencing — the cellular machinery for recovery remains present. Remove the NF-κB-activating cytokine load and CBP is released; restore cAMP and CREB is phosphorylated; inhibit HDACs and chromatin accessibility is restored. This reversibility is the mechanistic basis for the clinical response to immunoglobulin therapy in State 1 patients.

Autoantibody-mediated functional silencing

Simultaneously, the chronically activated adaptive immune system produces autoantibodies against neural surface proteins on SST-14 interneurons, impairing membrane signal transduction even when some SST-14 peptide production is partially maintained. Transcriptional suppression reduces SST-14 production at the gene level; autoantibody binding impairs the functional output of whatever signaling remains.

Convergence on SST-14 Interneuron Silencing and the Self-Reinforcing Biological Latch

The two arms of SST-14 silencing now arrive at the same cellular target simultaneously, along with epigenetic reinforcement from methylation failure and autoantibody-mediated surface receptor jamming. SST-14 interneurons are being suppressed at four independent levels simultaneously: metabolic depletion from quinolinic acid excitotoxicity, transcriptional suppression via NF-κB, reduced cAMP activation of CREB via adenosine, and surface receptor jamming via autoantibodies.

The A1 astrocyte shift and the loss of neural plasticity

Microglial activation driven by persistent LPS translocation and SST-14 loss of anti-inflammatory output produces IL-1α, TNF-α, and complement component C1q — the three signals that drive astrocyte polarization toward the A1 reactive phenotype. A2 astrocytes support synaptogenesis, produce BDNF and the synaptogenic proteins hevin and SPARCL1 that drive thalamocortical connectivity, and promote synaptic pruning accuracy. A1 reactive astrocytes suppress all of these functions.

The A1/A2 transition is not permanent. Liddelow et al.^[9] established that the A1 reactive state is maintained by ongoing microglial signaling and reverses when those signals are removed — a direct rebuttal of the assumption that the adult brain's developmental window is irreversibly closed.

The self-reinforcing biological latch

SST-14 silencing removes the anti-inflammatory inhibitory tone that SST-14 interneurons normally exert on microglia and reactive astrocytes. When SST-14 output falls, microglial reactivity increases, A1 polarization deepens, cytokine levels rise, IDO1 activity increases, and excitotoxic pressure on the remaining SST-14 interneurons intensifies. The system cannot self-correct because the mechanism that should initiate correction — SST-14 anti-inflammatory output — is the mechanism that has been disabled.

Neuropeptide Cascade Disruption: Oxytocin, VIP, and Secretin

Oxytocin: loss of coordinated social salience signaling

SST-14 interneurons in the paraventricular nucleus modulate the timing and amplitude of oxytocin release in response to social and safety signals. When SST-14 output is suppressed, oxytocin release becomes blunted, irregular, and uncoupled from social context. The clinical consequence is a motivational deficit at the neurochemical level — not the absence of social capacity but the absence of the signal that makes social interaction feel rewarding. The definitive null result from the SOARS-B trial^[7] (n=290) confirms that exogenous oxytocin cannot restore the circuit timing and social-contextual coupling that SST-14 interneuron coordination provides.

VIP: G-protein cascade failure across four biological systems

Vasoactive intestinal peptide (VIP) signaling operates through the canonical G-protein cascade: receptor → Gαs → adenylyl cyclase → cAMP → protein kinase A (PKA) → CREB. In the immune-derived autism cascade this chain has been disrupted at three independent points simultaneously: adenosine-driven Gαi suppression of adenylyl cyclase; SST-14 silencing removing coordinating inhibitory tone; and NF-κB directly suppressing CREB.

The four systems simultaneously disrupted by VIP loss are: the suprachiasmatic nucleus circadian clock (producing the fragmented, arrhythmic sleep of ASD); cortical inhibitory interneuron networks (producing modality-nonspecific sensory processing abnormalities); enteric smooth muscle peristalsis (producing constipation and irregular transit); and pro-inflammatory cytokine suppression in the immune system (removing an anti-inflammatory brake at the moment most required).

The estrogen-cAMP-CREB-SST14 compensatory axis and the male-to-female ratio

Estradiol activates adenylyl cyclase through a non-classical membrane-initiated pathway: membrane-associated estrogen receptor alpha couples to Gαq, activates protein kinase C, upregulates adenylyl cyclase VII, and generates cAMP independently of the Gαi-mediated adenosine suppression.^[2] Because the somatostatin gene contains a cyclic AMP response element (CRE),^[1] this estradiol-generated cAMP drives SST-14 gene transcription through CREB — providing partially compensatory transcriptional activation that counteracts the NF-κB-mediated CREB suppression. A female carrying equivalent upstream cascade burden retains a degree of SST-14 expression that a male with identical biology cannot access. At puberty, testosterone-to-estradiol conversion through brain aromatase provides prepubertal males with their first access to this compensatory pathway — accounting for the spontaneous improvement in social and behavioral function that families frequently report at puberty in male autistic children.

Secretin: compound failure from above and below

Secretin faces disruption from two independent directions. From below: gut pH dysregulation prevents duodenal chyme from reaching the pH 4.2 threshold required for S-cell secretin release; gut SST-28 overactivation provides a second suppressive layer through paracrine D-cell signaling. From above: SST-14 silencing removes the central neural coordination that secretin signaling requires for its brain-side effects in the cerebellum, hippocampus, and hypothalamus.

The early positive signal from Horvath et al.^[3] reflected intravenous delivery bypassing the blocked gut release mechanism entirely, delivering secretin to a genuinely secretin-deficient circuit. The subsequent 14 null RCTs^[4,5] enrolled unselected populations, diluting the responsive secretin-deficient subgroup to statistical insignificance.

Thalamic gating failure: a second mechanism for sensory dysregulation

SST-14 interneuron silencing in the thalamic reticular nucleus (TRN) provides a second anatomically upstream mechanism for sensory processing abnormalities. The TRN gates sensory information flow from thalamic relay nuclei to primary sensory cortices across all sensory modalities except olfaction. When TRN SST-14 interneurons are silenced, the thalamic gate is held open continuously — producing the two-level sensory filtering failure, in series with cortical VIP-driven gain control failure, that explains both the severity and modality-nonspecific nature of ASD sensory processing abnormalities.

The ASD Phenotype Cluster: Observable Expressions of Upstream Cascade Failure

The clinical features of immune-derived autism are not a collection of independently caused characteristics. They are simultaneous downstream expressions of a unified upstream mechanism organized by the neuropeptide system whose loss produces each domain of impairment.

Social motivation and emotional regulation — oxytocin pathway loss — reflects a motivational architecture failure rather than a structural inability to engage socially. Behavioral therapies providing external social scaffolding address the expression of the deficit; restoring upstream SST-14 interneuron coordination addresses its neurochemical source.

Sensory processing, sleep architecture, and gut motility — VIP pathway loss — spans four systems simultaneously. Sleep disruption (affecting 40–80% of autistic individuals) reflects loss of VIP-mediated circadian oscillator synchronization. Sensory processing abnormalities reflect two-level filtering failure. GI motility disturbance reflects VIP-driven smooth muscle relaxation failure. Treating each domain as an independent problem requiring its own specialist and intervention addresses consequences without engaging the upstream failure producing all of them.

Digestive function, cerebellar development, and gut-brain metabolism — secretin pathway loss — bridges gut and brain simultaneously. The cerebellar component produces motor coordination difficulties, simplified gait patterns including idiopathic toe walking, and impaired procedural learning.

Cognitive rigidity and impaired neural plasticity — A1 astrocyte polarization — produces reduced synaptogenesis, impaired synaptic pruning accuracy, BDNF deficiency, and withdrawal of hevin/SPARCL1-mediated thalamocortical connectivity. As established by Liddelow et al.,^[9] this A1 polarization state reverses when inflammatory signals are removed — challenging the clinical assumption that neural plasticity windows close irreversibly in early childhood.

Synthesis: The Convergent Cascade, Clinical Implications, and Testable Predictions

Why prior clinical trials failed to demonstrate benefit

The trial literature for oxytocin, secretin, and immunoglobulin interventions in ASD has produced inconsistent results explained by two systematic design failures: intervention at a downstream rather than upstream mechanistic point, and enrollment of unselected populations that include non-immune-derived ASD subtypes.

The Frye et al. series on folinic acid in folate-receptor-antibody-positive ASD^[11,12,13] represents the single published intervention producing consistent positive results — following directly from prospective biomarker-stratified patient selection identifying the subgroup for whom the specific biological mechanism targeted by the intervention is operative.

Regressive autism and PANS/PANDAS as temporal expressions of the same cascade

Regressive autism is not a mechanistically distinct subtype but a temporal expression of the cascade under threshold dynamics. Compensatory mechanisms may maintain adequate SST-14 interneuron output while cascade burden accumulates. A second biological challenge crosses the threshold at which SST-14 interneurons can no longer maintain coordinating output. The regression is the moment the threshold was crossed, not the moment pathology began.

Pediatric acute-onset neuropsychiatric syndrome (PANS) and its streptococcal-associated variant (PANDAS) represent the accelerated acute expression of the same cascade. Streptococcal molecular mimicry drives rapid autoantibody production against neural surface proteins on SST-14 interneurons and basal ganglia neurons — the same autoantibody mechanism that constitutes State 1 SST-14 surface receptor jamming in the chronic cascade.

ADHD and AuDHD as regional variants of SST-14 silencing

The clinical distinction between ASD and ADHD, and the high co-occurrence producing the AuDHD combined presentation, may reflect the regional distribution of SST-14 silencing: predominant prefrontal silencing produces ADHD-predominant features; predominant hypothalamic, amygdala, and sensory cortex silencing produces ASD-predominant features; extensive silencing across both regions produces the combined AuDHD presentation.

Testable predictions arising from the convergent cascade model

The model generates specific predictions testable in existing datasets and prospective biomarker studies: plasma quinolinic acid should correlate with SST-14 peptide levels in ASD populations; the K:T ratio should predict clinical response to immunoglobulin therapy;^[33] lactate-to-pyruvate ratio should predict the requirement for mitochondrial restoration; female ASD individuals should show higher SST-14 peptide levels than males with equivalent cytokine and autoantibody profiles; autistic males with documented pubertal aromatase activity should show greater spontaneous improvement in SST-14-dependent outcomes.

Implications beyond ASD

SST-14 interneuron loss is one of the earliest and most consistent neuropathological findings in Alzheimer's disease, strongly correlating with episodic memory impairment.^[27] Chronic intestinal inflammation and LPS translocation in Crohn's disease activate the same IDO1-kynurenine-quinolinic acid axis observed in the immune-derived autism cascade. Immune-derived autism, Crohn's disease, and late-onset Alzheimer's disease may represent different temporal and tissue-specific expressions of a shared metabolic-inflammatory diathesis centered on gut barrier dysfunction, kynurenine pathway activation, and SST interneuron impairment.

Limitations and scope

This document presents a mechanistic hypothesis integrating published primary literature across multiple biological systems. The complete cascade as an integrated model is novel and has not been prospectively tested as a unified framework. Individual mechanistic steps are supported by published primary literature; the integrated chain awaits prospective validation. The model does not claim to explain all autism spectrum disorder. Primarily genetic ASD subtypes — Fragile X, Rett syndrome, Angelman syndrome, tuberous sclerosis — involve mechanisms distinct from the immune-derived cascade described here.

The mechanistic links carry substantially different levels of empirical support. The IDO1-kynurenine pathway diversion, cytokine elevation, and downstream quinolinic acid excitotoxicity are strongly supported by multiple independent human ASD cohort studies with direct measurement. The CD26/DPP-IV blockade by casomorphin and gliadorphin is supported by in vitro binding demonstrations and indirect metabolomics evidence, though prospective human studies directly measuring the full sequence remain limited. The pepsin pH-dependence mechanism has not been prospectively tested in ASD populations as a primary cascade driver. Readers should interpret the document accordingly: downstream mechanisms are better evidenced than the upstream initiating sequence.

Conclusion

Immune-derived autism is produced by a converging multi-step biological cascade originating in gut pH dysregulation and arriving, through immune activation and metabolic disruption, at the silencing of SST-14 interneurons. The silencing of these interneurons simultaneously disrupts the coordinated release of oxytocin, VIP, and secretin, producing the social, sensory, sleep, gastrointestinal, motor, and cognitive features of the ASD phenotype cluster. The cascade is self-reinforcing, sex-differentiated by a specific molecular mechanism involving the estrogen-cAMP-CREB-SST14 compensatory axis, and reversible in the subset where the silencing mechanism remains transcriptional rather than structural.

Three decades of clinical trials in ASD have produced inconsistent results because they targeted downstream neuropeptide outputs rather than the upstream converging mechanism, and enrolled biologically heterogeneous populations rather than the biomarker-defined subgroup for whom each intervention was mechanistically relevant.

Companion document: Restoring the Somatostatin Signal in Immune-Derived ASD: Using IMIG, IVIG, and MSC Therapy as Parallel Pathways to Neuropeptide Cascade Recovery · decodingautismnow.com · June 2026